David Feldman
#141,381
Most Influential Person Across History
David Feldman's AcademicInfluence.com Rankings
David Feldmanbiology Degrees
Biology
#7852
Historical Rank
Molecular Biology
#487
Historical Rank
Biochemistry
#724
Historical Rank
Download Badge
Philosophy Biology
David Feldman's Degrees
- Doctorate Medicine Stanford University
Why Is David Feldman Influential?
(Suggest an Edit or Addition)David Feldman's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- The development of androgen-independent prostate cancer (2001) (2370)
- Bisphenol-A: an estrogenic substance is released from polycarbonate flasks during autoclaving. (1993) (1532)
- The role of vitamin D in reducing cancer risk and progression (2014) (988)
- 1,25-dihydroxyvitamin D3 and malignant melanoma: the presence of receptors and inhibition of cell growth in culture. (1981) (578)
- Antiproliferative effects of 1,25-dihydroxyvitamin D3 on primary cultures of human prostatic cells. (1994) (531)
- Glucocorticoids can promote androgen-independent growth of prostate cancer cells through a mutated androgen receptor (2000) (523)
- Vitamin D and prostate cancer: 1,25 dihydroxyvitamin D3 receptors and actions in human prostate cancer cell lines. (1993) (493)
- Inhibition of adrenal steroidogenesis by the anesthetic etomidate. (1984) (487)
- Point mutations in the human vitamin D receptor gene associated with hypocalcemic rickets. (1988) (460)
- Mechanisms of the anti-cancer and anti-inflammatory actions of vitamin D. (2011) (443)
- Ketoconazole blocks adrenal steroidogenesis by inhibiting cytochrome P450-dependent enzymes. (1983) (420)
- Ketoconazole blocks adrenal steroid synthesis. (1982) (402)
- The vitamin D receptor and the syndrome of hereditary 1,25-dihydroxyvitamin D-resistant rickets. (1999) (365)
- Treatment of early recurrent prostate cancer with 1,25-dihydroxyvitamin D3 (calcitriol) (1998) (313)
- The Vitamin D Receptor Start Codon Polymorphism (FokI) and Bone Mineral Density in Premenopausal American Black and White Women (1997) (290)
- Unraveling insulin-like growth factor binding protein-3 actions in human disease. (2009) (282)
- Subcellular mechanisms in the action of adrenal steroids. (1972) (240)
- The Vitamin D Receptor Gene Start Codon Polymorphism: A Functional Analysis of FokI Variants (1998) (239)
- Regulation of prostaglandin metabolism by calcitriol attenuates growth stimulation in prostate cancer cells. (2005) (231)
- The roles of plasma binding and receptor specificity in the mineralocorticoid action of aldosterone. (1973) (228)
- Reduced 1alpha-hydroxylase activity in human prostate cancer cells correlates with decreased susceptibility to 25-hydroxyvitamin D3-induced growth inhibition. (2001) (218)
- Actions of vitamin D3, analogs on human prostate cancer cell lines: comparison with 1,25-dihydroxyvitamin D3. (1995) (209)
- Ketoconazole and other imidazole derivatives as inhibitors of steroidogenesis. (1986) (208)
- Estrogens inhibit mycelium-to-yeast transformation in the fungus Paracoccidioides brasiliensis: implications for resistance of females to paracoccidioidomycosis (1984) (207)
- Vitamin D Growth Inhibition of Breast Cancer Cells: Gene Expression Patterns Assessed by cDNA Microarray (2003) (199)
- Inhibition of p38 by vitamin D reduces interleukin-6 production in normal prostate cells via mitogen-activated protein kinase phosphatase 5: implications for prostate cancer prevention by vitamin D. (2006) (196)
- The role of vitamin D in cancer prevention and treatment. (2012) (195)
- Insulin-like growth factor binding protein-3 mediates 1 alpha,25-dihydroxyvitamin d(3) growth inhibition in the LNCaP prostate cancer cell line through p21/WAF1. (2001) (191)
- Demonstration of 1,25-dihydroxyvitamin D3 receptors in human skin biopsies. (1980) (187)
- The molecular basis of hereditary 1,25-dihydroxyvitamin D3 resistant rickets in seven related families. (1990) (178)
- Inhibition of prostate cancer growth by vitamin D: Regulation of target gene expression (2003) (178)
- Glucocorticoid receptors in rat kidney: the binding of tritiated-dexamethasone. (1973) (166)
- 1,25-dihydroxyvitamin D3 receptors and hormonal responses in cloned human skeletal muscle cells. (1986) (161)
- Glucocorticoid receptors and inhibition of bone cell growth in primary culture. (1977) (157)
- Organ distribution of the cytoplasmic 1,25-dihydroxycholecalciferol receptor in various mouse tissues. (1980) (156)
- Vitamin D resistant rickets with alopecia: cultured skin fibroblasts exhibit defective cytoplasmic receptors and unresponsiveness to 1,25(OH)2D3. (1982) (147)
- Consensus statement from 2nd International Conference on Controversies in Vitamin D (2020) (144)
- Analysis of vitamin D‐regulated gene expression in LNCaP human prostate cancer cells using cDNA microarrays (2004) (144)
- Lack of Correlation Between Start Codon Polymorphism of the Vitamin D Receptor Gene and Bone Mineral Density in Premenopausal French Women: The OFELY Study (1998) (143)
- Regulation of 1,25-dihydroxyvitamin D3 receptors by vitamin D analogs in cultured mammalian cells. (1985) (143)
- Identification of a functional vitamin D response element in the human insulin-like growth factor binding protein-3 promoter. (2004) (140)
- 1α,25-Dihydroxyvitamin D3 Down-Regulates Estrogen Receptor Abundance and Suppresses Estrogen Actions in MCF-7 Human Breast Cancer Cells (2000) (138)
- The role of vitamin D in prostate cancer (2001) (137)
- Molecular pathways mediating the anti-inflammatory effects of calcitriol: implications for prostate cancer chemoprevention and treatment. (2010) (134)
- Regulation of vitamin D receptor abundance and responsiveness during differentiation of HT-29 human colon cancer cells. (1993) (134)
- Genetic disorders and defects in vitamin d action. (2010) (134)
- Estradiol binds to a receptor-like cytosol binding protein and initiates a biological response in Paracoccidioides brasiliensis. (1983) (132)
- Liarozole Acts Synergistically with 1α,25-Dihydroxyvitamin D3 to Inhibit Growth of DU 145 Human Prostate Cancer Cells by Blocking 24-Hydroxylase Activity. (1999) (131)
- Hereditary vitamin D resistant rickets caused by a novel mutation in the vitamin D receptor that results in decreased affinity for hormone and cellular hyporesponsiveness. (1997) (129)
- An ochre mutation in the vitamin D receptor gene causes hereditary 1,25-dihydroxyvitamin D3-resistant rickets in three families. (1989) (126)
- 1 alpha,25-dihydroxyvitamin D3 receptors in cultured rat osteoblast-like cells. Glucocorticoid treatment increases receptor content. (1983) (125)
- Glucocorticoid receptors and actions in subpopulations of cultured rat bone cells. Mechanism of dexamethasone potentiation of parathyroid hormone-stimulated cyclic AMP production. (1979) (124)
- Dietary vitamin D₃ and 1,25-dihydroxyvitamin D₃ (calcitriol) exhibit equivalent anticancer activity in mouse xenograft models of breast and prostate cancer. (2012) (122)
- Evidence for a new class of corticosterone receptors in the rat kidney. (1973) (120)
- Vitamin D and breast cancer: Inhibition of estrogen synthesis and signaling (2010) (120)
- 1,25-Dihydroxyvitamin D3 decreases human prostate cancer cell adhesion and migration (2000) (119)
- Molecular mechanisms mediating the anti-proliferative effects of Vitamin D in prostate cancer (2005) (117)
- Distinction between alpha-fetoprotein and intracellular estrogen receptors: evidence against the presence of estradiol receptors in rat bone. (1978) (114)
- Molecular activity of 1,25-dihydroxyvitamin D3 in primary cultures of human prostatic epithelial cells revealed by cDNA microarray analysis (2004) (114)
- Two mutations identified in the androgen receptor of the new human prostate cancer cell line MDA PCa 2a. (1999) (114)
- Specific aldosterone binding in rat kidney and parotid. (1972) (113)
- Candida albicans estrogen-binding protein gene encodes an oxidoreductase that is inhibited by estradiol. (1994) (112)
- Characterization of a cytoplasmic receptor-like binder for 1 alpha, 25-dihydroxycholecalciferol in rat intestinal mucosa. (1979) (111)
- Renal aldosterone receptors: studies with (3H)aldosterone and the anti-mineralocorticoid (3H)spirolactone (SC-26304). (1974) (110)
- Homologous up-regulation of the 1,25 (OH)2 vitamin D3 receptor in rats. (1986) (108)
- Ketoconazole binds to glucocorticoid receptors and exhibits glucocorticoid antagonist activity in cultured cells. (1983) (108)
- 1α,25-Dihydroxyvitamin D3 Inhibits Prostate Cancer Cell Growth by Androgen-Dependent and Androgen-Independent Mechanisms. (2000) (107)
- Regulation of 1,25-dihydroxyvitamin D3 receptors in cultured mouse bone cells. Correlation of receptor concentration with the rate of cell division. (1981) (107)
- Effects of Dexmedetomidine, a Novel Imidazole Sedative‐Anesthetic Agent, on Adrenal Steroidogenesis: In Vivo and In Vitro Studies (1991) (107)
- Vitamin D and prostate cancer. (2007) (107)
- Erratum: Glucocorticoids can promote androgen-independent growth of prostate cancer cells through a mutated androgen receptor (Nature Medicine (2000) 6 (703-706)) (2000) (107)
- The effects of 1,25-dihydroxyvitamin D3 and dexamethasone on rat osteoblast-like primary cell cultures: receptor occupancy and functional expression patterns for three different bioresponses. (1986) (106)
- Calcium plus vitamin D supplementation and the risk of nonmelanoma and melanoma skin cancer: post hoc analyses of the women's health initiative randomized controlled trial. (2011) (105)
- Molecular modifications of anti-aldosterone compounds: effects on affinity of spirolactones for renal aldosterone receptors. (1974) (102)
- Tissue-Selective Regulation of Aromatase Expression by Calcitriol: Implications for Breast Cancer Therapy. (2009) (100)
- 1α,25-Dihydroxyvitamin D3 Actions in LNCaP Human Prostate Cancer Cells Are Androgen-Dependent. (1997) (100)
- 1,25-Dihydroxyvitamin D resistance, rickets, and alopecia. (1984) (100)
- Editorial/Mini-Review: Vitamin D and Prostate Cancer. (2000) (100)
- A receptor-like binding macromolecule for 1 alpha, 25-dihydroxycholecalciferol in cultured mouse bone cells. (1979) (97)
- Interaction of the vitamin D receptor with a vitamin D response element in the Mullerian-inhibiting substance (MIS) promoter: regulation of MIS expression by calcitriol in prostate cancer cells. (2009) (97)
- Vitamin D: Biology, Actions, and Clinical Implications (2001) (96)
- Tissue-selective regulation of aromatase expression by calcitriol: implications for breast cancer therapy. (2009) (96)
- 1,25-dihydroxyvitamin D3 receptors in human epithelial cancer cell lines. (1982) (94)
- Novel pathways that contribute to the anti-proliferative and chemopreventive activities of calcitriol in prostate cancer (2007) (93)
- Vitamin D resistance and alopecia: a kindred with normal 1,25-dihydroxyvitamin D binding, but decreased receptor affinity for deoxyribonucleic acid. (1985) (92)
- The role of vitamin D receptor mutations in the development of alopecia (2011) (91)
- Inhibition of steroidogenic cytochrome P-450 enzymes in rat testis by ketoconazole and related imidazole anti-fungal drugs. (1985) (91)
- The anti-cancer and anti-inflammatory actions of 1,25(OH)₂D₃. (2011) (91)
- Characterization of insulin-like growth factor I receptors on cultured rat bone cells: regulation of receptor concentration by glucocorticoids. (1984) (90)
- ACTH-independent massive bilateral adrenal disease (AIMBAD): a subtype of Cushing's syndrome with major diagnostic and therapeutic implications. (1994) (90)
- Risk Factors for Sleep Disordered Breathing in Heterogeneous Geriatric Populations (1987) (89)
- Genistein potentiates the growth inhibitory effects of 1,25-dihydroxyvitamin D3 in DU145 human prostate cancer cells: Role of the direct inhibition of CYP24 enzyme activity (2005) (86)
- Induction of Androgen Receptor by 1α,25-Dihydroxyvitamin D3 and 9-cis Retinoic Acid in LNCaP Human Prostate Cancer Cells. (1999) (86)
- Pathways mediating the growth-inhibitory actions of vitamin D in prostate cancer. (2003) (85)
- Hereditary 1,25-Dihydroxyvitamin D-resistant rickets. (1997) (84)
- An estrogen-binding protein and endogenous ligand in Saccharomyces cerevisiae: possible hormone receptor system. (1982) (84)
- Abnormal binding of vitamin D receptors to deoxyribonucleic acid in a kindred with vitamin D-dependent rickets, type II. (1989) (83)
- A novel mutation in helix 12 of the vitamin D receptor impairs coactivator interaction and causes hereditary 1,25-dihydroxyvitamin D-resistant rickets without alopecia. (2002) (83)
- Dexamethasone increases 1,25-dihydroxyvitamin D3 receptor levels and augments bioresponses in rat osteoblast-like cells. (1986) (82)
- Glucocorticoid and estrogen regulation of corticosteroid-binding globulin production by rat liver. (1979) (82)
- Stimulation of 1,25‐dihydroxyvitamin D3 receptor gene expression in cultured cells by serum and growth factors (1991) (82)
- Mutations in the vitamin D receptor and hereditary vitamin D-resistant rickets. (2014) (82)
- Preclinical activity of ketoconazole in combination with calcitriol or the vitamin D analogue EB 1089 in prostate cancer cells. (2002) (81)
- Risk of early-onset prostate cancer in relation to germ line polymorphisms of the vitamin D receptor. (2004) (80)
- Demonstration of glucocorticoid receptors in the adrenal cortex: evidence for a direct dexamethasone suppressive effect on the rat adrenal gland. (1980) (80)
- Vitamin D receptor gene polymorphisms: analysis of ligand binding and hormone responsiveness in cultured skin fibroblasts. (1998) (80)
- 1alpha,25-Dihydroxyvitamin D3 down-regulates estrogen receptor abundance and suppresses estrogen actions in MCF-7 human breast cancer cells. (2000) (80)
- Prostate specific antigen levels in young adulthood predict prostate cancer risk: results from a cohort of Black and White Americans. (2005) (79)
- Estrogens in unexpected places: possible implications for researchers and consumers. (1995) (78)
- A corticosteroid binding protein and endogenous ligand in C. albicans indicating a possible steroid-receptor system (1981) (77)
- The potential therapeutic benefits of vitamin D in the treatment of estrogen receptor positive breast cancer (2012) (77)
- The role of the vitamin D receptor and ERp57 in photoprotection by 1α,25-dihydroxyvitamin D3. (2012) (77)
- Glucocorticoid receptors in adipose tissue. (1977) (76)
- Photoprotection by 1α,25-dihydroxyvitamin D and analogs: Further studies on mechanisms and implications for UV-damage (2010) (75)
- Prostatic soy isoflavone concentrations exceed serum levels after dietary supplementation (2009) (75)
- 1,25-dihydroxyvitamin D resistance, rickets, and alopecia: analysis of receptors and bioresponse in cultured fibroblasts from patients and parents. (1984) (74)
- Calcitriol as a Chemopreventive and Therapeutic Agent in Prostate Cancer: Role of Anti‐Inflammatory Activity (2007) (73)
- Cyclic adenosine 3',5'-monophosphate up-regulates 1,25-dihydroxyvitamin D3 receptor gene expression and enhances hormone action. (1992) (72)
- Mutant vitamin D receptors which confer hereditary resistance to 1,25-dihydroxyvitamin D3 in humans are transcriptionally inactive in vitro. (1989) (72)
- Ontogeny of rat hepatic glucocorticoid receptors. (1974) (71)
- Characterization of an estrogen-binding protein in the yeast Saccharomyces cerevisiae. (1984) (70)
- A glucocorticoid-responsive mutant androgen receptor exhibits unique ligand specificity: therapeutic implications for androgen-independent prostate cancer. (2002) (70)
- Vitamin D receptor start codon polymorphism (FokI) and prostate cancer progression. (2003) (69)
- Glucocorticoid regulation of 1,25(OH)2vitamin D3 receptors: divergent effects on mouse and rat intestine. (1982) (68)
- Inhibition of prostaglandin synthesis and actions by genistein in human prostate cancer cells and by soy isoflavones in prostate cancer patients (2009) (68)
- Glucocorticoid modulation of cell proliferation in cultured osteoblast-like bone cells: differences between rat and mouse. (1983) (68)
- Cytoplasmic glucocorticoid binding proteins in bone cells. (1975) (67)
- Glucocorticoid potentiation of the adenosin 3',5'-monophosphate response to parathyroid hormone in cultured rat bone cells. (1978) (67)
- Characterization of an estrogen-binding protein in the yeast Candida albicans. (1989) (65)
- Hormonal responses to 1,25‐dihydroxyvitamin D3 in cultured mouse osteoblast‐like cells—modulation by changes in receptor level (1986) (64)
- 1alpha,25-dihydroxyvitamin D3 actions in LNCaP human prostate cancer cells are androgen-dependent. (1997) (64)
- Characterization of a unique corticosterone-binding protein in Candida albicans. (1982) (64)
- Activation of protein kinase-C inhibits vitamin D receptor gene expression. (1991) (64)
- Glucocorticoid regulation of 1,25(OH)2-vitamin D3 receptors in cultured mouse bone cells. (1982) (63)
- Relations between obesity, insulin resistance, and 25-hydroxyvitamin D. (2012) (63)
- Liarozole acts synergistically with 1alpha,25-dihydroxyvitamin D3 to inhibit growth of DU 145 human prostate cancer cells by blocking 24-hydroxylase activity. (1999) (62)
- A novel mutation in the deoxyribonucleic acid-binding domain of the vitamin D receptor causes hereditary 1,25-dihydroxyvitamin D-resistant rickets. (1996) (62)
- Estradiol-binding proteins from mycelial and yeast-form cultures of Paracoccidioides brasiliensis (1986) (61)
- Regulation of 1,25-dihydroxyvitamin D3 receptors by parathyroid hormone in osteoblastic cells: role of second messenger pathways. (1995) (60)
- A phase II trial of calcitriol and naproxen in recurrent prostate cancer. (2009) (60)
- Androgen–glucocorticoid interactions in the era of novel prostate cancer therapy (2016) (60)
- Vitamin D resistance. (1999) (60)
- Synthesis and secretion of corticosteroid-binding globulin by rat liver. A source of heterogeneity of hepatic corticosteroid-binders. (1979) (59)
- Hereditary 1 alpha,25-dihydroxyvitamin D-resistant rickets resulting from a mutation in the vitamin D receptor deoxyribonucleic acid-binding domain. (1994) (59)
- Measurement of 1,25-dihydroxyvitamin D3 receptor turnover by dense amino acid labeling: changes during receptor up-regulation by vitamin D metabolites. (1987) (59)
- Calcitriol and genistein actions to inhibit the prostaglandin pathway: potential combination therapy to treat prostate cancer. (2007) (58)
- Androgen and vitamin D receptor gene polymorphisms: the long and short of prostate cancer risk. (1997) (57)
- Mechanisms of vitamin D-mediated growth inhibition in prostate cancer cells: inhibition of the prostaglandin pathway. (2006) (57)
- Inhibition of Mouse Breast Tumor-Initiating Cells by Calcitriol and Dietary Vitamin D (2015) (55)
- Inhibitory Effects of Calcitriol on the Growth of MCF-7 Breast Cancer Xenografts in Nude Mice: Selective Modulation of Aromatase Expression in vivo (2011) (55)
- The role of vitamin D in cancer prevention and treatment. (2010) (54)
- Genetic defects of the 1,25-dihydroxyvitamin D3 receptor. (1991) (54)
- 1alpha,25-dihydroxyvitamin D3 inhibits prostate cancer cell growth by androgen-dependent and androgen-independent mechanisms. (2000) (54)
- Fulvestrant (ICI 182,780) down-regulates androgen receptor expression and diminishes androgenic responses in LNCaP human prostate cancer cells (2006) (53)
- Cloning and expression of the gene from Candida albicans that encodes a high-affinity corticosteroid-binding protein. (1993) (53)
- Parathyroid hormone‐related protein (PTHrP) is an epidermal growth factor‐regulated secretory product of human prostatic epithelial cells (1996) (52)
- Vitamin D metabolism and action in the prostate: Implications for health and disease (2011) (52)
- Estradiol inhibits glucocorticoid receptor expression and induces glucocorticoid resistance in MCF-7 human breast cancer cells (2001) (52)
- A novel inborn error in the ligand-binding domain of the vitamin D receptor causes hereditary vitamin D-resistant rickets. (2001) (51)
- The role of vitamin D and retinoids in controlling prostate cancer progression. (2003) (50)
- Hereditary 1,25-dihydroxyvitamin D resistant rickets due to a mutation causing multiple defects in vitamin D receptor function. (2004) (50)
- 19-Nor deoxycorticosterone (19-nor DOC): mineralocorticoid receptor affinity higher than aldosterone, electrolyte activity lower. (1978) (50)
- The role of vitamin D and SLCO1B1 gene polymorphism in statin-associated myalgias (2010) (49)
- Inhibition of androgen receptor signaling by selenite and methylseleninic acid in prostate cancer cells: two distinct mechanisms of action (2006) (49)
- CHAPTER 63 – Vitamin D and the Pathogenesis of Rickets and Osteomalacia (1997) (49)
- Retinoic acid modulation of 1,25(OH)2 vitamin D3 receptors and bioresponse in bone cells: species differences between rat and mouse. (1985) (48)
- Equivalent anticancer activities of dietary vitamin D and calcitriol in an animal model of breast cancer: Importance of mammary CYP27B1 for treatment and prevention (2013) (48)
- Hereditary 1,25-dihydroxyvitamin D resistant rickets: Molecular basis and implications for the role of 1,25(OH)2D3 in normal physiology (1990) (47)
- Vitamin D receptor mutations in patients with hereditary 1,25-dihydroxyvitamin D-resistant rickets. (2014) (46)
- CHAPTER 66 – Vitamin D Insufficiency in Adults and the Elderly (1997) (46)
- Is the glucocorticoid receptor identical in various target organs? (1978) (46)
- Dermatophyte-hormone relationships: characterization of progesterone-binding specificity and growth inhibition in the genera Trichophyton and Microsporum (1988) (46)
- PPARgamma agonists enhance human vascular endothelial adhesiveness by increasing ICAM-1 expression. (1999) (46)
- Vitamin D: anticancer and differentiation. (1997) (45)
- Identification of 17 beta-estradiol as the estrogenic substance in Saccharomyces cerevisiae. (1984) (45)
- Induction of androgen receptor by 1alpha,25-dihydroxyvitamin D3 and 9-cis retinoic acid in LNCaP human prostate cancer cells. (1999) (45)
- Interactions of the Vitamin D Receptor with the Corepressor Hairless (2007) (44)
- Intrinsic mineralocorticoid agonist activity of some nonsteroidal anti-inflammatory drugs. A postulated mechanism for sodium retention. (1976) (44)
- Effects of Vitamin D on Skeletal Muscle and Athletic Performance. (2018) (44)
- Genetic disorders and defects in vitamin D action. (2012) (44)
- Heterogeneity of glucocorticoid binders: a unique and a classical dexamethasone-binding site in bovine tissues. (1979) (44)
- 1,25-Dihydroxyvitamin D3 receptors and functions in cultured pig kidney cells (LLC PK1). Regulation of 24,25-dihydroxyvitamin D3 production. (1982) (44)
- CHAPTER 67 – Vitamin D and Osteoporosis (1997) (43)
- Agonist and antimineralocorticoid activities of spirolactones. (1976) (43)
- Interaction of nuclear receptor ligands with the Vitamin D signaling pathway in prostate cancer (2004) (43)
- Demonstration of a 1,25-dihydroxycholecalciferol cytoplasmic receptor-like binder in mouse kidney. (1979) (43)
- Mechanisms of decreased Vitamin D 1α-hydroxylase activity in prostate cancer cells (2004) (43)
- Hereditary 1,25‐Dihydroxyvitamin D–Resistant Rickets Due to an Opal Mutation Causing Premature Termination of the Vitamin D Receptor (1998) (41)
- Distribution of a corticosteroid-binding protein in Candida and other fungal genera. (1983) (41)
- Hereditary 1,25-dihydroxyvitamin D-resistant rickets with alopecia resulting from a novel missense mutation in the DNA-binding domain of the vitamin D receptor. (2010) (40)
- Vitamin D, parathyroid hormone, and calcium: a complex regulatory network. (1999) (39)
- 1,25-Dihydroxyvitamin D3 Induction of Nerve Growth Factor in L929 Mouse Fibroblasts: Effect of Vitamin D Receptor Regulation and Potency of Vitamin D3 Analogs1. (1997) (39)
- Low circulating 25-hydroxyvitamin D concentrations are associated with defects in insulin action and insulin secretion in persons with prediabetes. (2015) (39)
- Transrepression of the estrogen receptor promoter by calcitriol in human breast cancer cells via two negative vitamin D response elements. (2013) (39)
- Autoradiographic localization of corticosterone receptors (type III) to the collecting tubule of the rat kidney. (1975) (39)
- Sex steroid hormones in young manhood and the risk of subsequent prostate cancer: a longitudinal study in African-Americans and Caucasians (United States) (2006) (39)
- Progesterone binding and inhibition of growth in Trichophyton mentagrophytes (1986) (37)
- Analysis of vitamin D analog-induced heterodimerization of vitamin D receptor with retinoid X receptor using the yeast two-hybrid system. (1997) (36)
- A Unique Insertion/Substitution in Helix H1 of the Vitamin D Receptor Ligand Binding Domain in a Patient With Hereditary 1,25‐Dihydroxyvitamin D‐Resistant Rickets (2004) (36)
- A unique insertion/duplication in the VDR gene that truncates the VDR causing hereditary 1,25-dihydroxyvitamin D-resistant rickets without alopecia. (2007) (36)
- Influence of oestradiol on protein expression and methionine utilization during morphogenesis of Paracoccidioides brasiliensis. (1989) (35)
- Vitamin D in the nervous system: actions and therapeutic potential. (1997) (35)
- A Rationale for Treatment of Hereditary Vitamin D-resistant Rickets with Analogs of 1α,25-Dihydroxyvitamin D3 * (2001) (35)
- The Binding of 18-Hydroxydeoxy corticosterone and 18-Hydroxycorticosterone to Mineralocorticoid and Glucocorticoid Receptors in the Rat Kidney1 (1973) (35)
- Oestrogen-binding protein in Candida albicans: antibody development and cellular localization by electron immunocytochemistry. (1995) (34)
- Hereditary vitamin D resistant rickets: identification of a novel splice site mutation in the vitamin D receptor gene and successful treatment with oral calcium therapy. (2009) (34)
- Hereditary vitamin D–resistant rickets (HVDRR) owing to a heterozygous mutation in the vitamin D receptor (2011) (34)
- Syndrome of lipoatrophic diabetes, vitamin D resistant rickets, and persistent Müllerian ducts in a Turkish boy born to consanguineous parents. (1996) (34)
- Estrogen down-regulation of androgen receptors in cultured human mammary cancer cells (MCF-7). (1987) (34)
- Diaminoindanes as microsomal triglyceride transfer protein inhibitors. (2001) (33)
- Glucocorticoids down-regulate the number of 1, 25-dihydroxyvitamin D3 receptors in mouse intestine. (1982) (33)
- Vitamin D mitigates the adverse effects of obesity on breast cancer in mice. (2016) (33)
- Nuclear translocation of the 1,25-dihydroxycholecalciferol receptor in mouse kidney. (1980) (32)
- Vitamin D and obstructive sleep apnea: a systematic review and meta-analysis. (2017) (32)
- A novel nonsense mutation in the ligand binding domain of the vitamin D receptor causes hereditary 1,25-dihydroxyvitamin D-resistant rickets. (2002) (32)
- Regulation of 1,25(OH)2 vitamin D3 receptor content in cultured LLC-PK1 kidney cells limits hormonal responsiveness. (1983) (32)
- Growth inhibitory concentrations of androgens up-regulate insulin-like growth factor binding protein-3 expression via an androgen response element in LNCaP human prostate cancer cells. (2006) (32)
- The role of vitamin D in prostate cancer. (2001) (32)
- Two New Unrelated Cases of Hereditary 1,25-Dihydroxyvitamin D-resistant Rickets with Alopecia resulting from the same Novel Nonsense Mutation in the Vitamin D Receptor Gene (2010) (30)
- Immunomodulatory and cell differentiation effects of vitamin D. (1997) (30)
- Rapid biological responses mediated by 1α,25-dihydroxyvitamin D3: a case study of transcaltachia (rapid hormonal stimulation of intestinal calcium transport). (1997) (30)
- Evidence that brown adipose tissue is a glucocorticoid target organ. (1978) (29)
- Receptor mediated glucocorticoid inhibition of protein synthesis in isolated bone cells. (1978) (29)
- Drug and Hormone Effects on Vitamin D Metabolism (1997) (28)
- CHAPTER 38 – Vitamin D and Osteoclastogenesis (1997) (28)
- The role of insulin‐like growth factor binding protein‐3 in the growth inhibitory actions of androgens in LNCaP human prostate cancer cells (2008) (28)
- Vitamin D inhibition of the prostaglandin pathway as therapy for prostate cancer. (2007) (27)
- Compound Heterozygous Mutations in the Vitamin D Receptor in a Patient With Hereditary 1,25‐Dihydroxyvitamin D‐Resistant Rickets With Alopecia (2009) (27)
- Combination of calcitriol and dietary soy exhibits enhanced anticancer activity and increased hypercalcemic toxicity in a mouse xenograft model of prostate cancer (2012) (27)
- Epidermal growth factor increases intestinal calbindin-D9k and 1,25-dihydroxyvitamin D receptors in neonatal rats. (1989) (26)
- Steroid metabolism as a mechanism of escape from progesterone-mediated growth inhibition in Trichophyton mentagrophytes. (1989) (26)
- Actions Of Vitamin D, Analogs on Human Prostate Cancer Cell Lines: Comparison with (1995) (26)
- Vitamin DBiology, Action, and Clinical Implications (2001) (25)
- The role of vitamin D3 in immunosuppression: lessons from autoimmunity and transplantation. (1997) (25)
- 1,25-dihydroxyvitamin D3 induction of nerve growth factor in L929 mouse fibroblasts: effect of vitamin D receptor regulation and potency of vitamin D3 analogs. (1997) (24)
- Steroidal 21-diazo ketones: photogenerated corticosteroid receptor labels. (1975) (24)
- Inactivation of the human vitamin D receptor by caspase-3. (2009) (24)
- Selenite treatment inhibits LAPC-4 tumor growth and prostate-specific antigen secretion in a xenograft model of human prostate cancer. (2008) (24)
- Nuclear vitamin D receptor: structure - function, phosphorylation, and control of gene transcription. (1997) (24)
- Rationale for combination ketoconazole/ vitamin D treatment of prostate cancer. (2001) (24)
- Extrarenal production and action of active vitamin D metabolites in human lymphoproliferative diseases. (1997) (23)
- Effects of 1α,25-dihydroxyvitamin D3 and glucocorticoids on the growth of rat and mouse osteoblast-like bone cells (1983) (23)
- Hereditary 1,25-dihydroxyvitamin D-resistant rickets in a Pomeranian dog caused by a novel mutation in the vitamin D receptor gene. (2009) (22)
- The role of hormone receptors in the action of adrenal steroids. (1975) (22)
- Simian virus 40-, but not human papillomavirus-, transformation of prostatic epithelial cells results in loss of growth-inhibition by 1,25-dihydroxyvitamin D-3. (1996) (21)
- Suramin, hydrocortisone, and retinoic acid modify inhibitory effects of 1,25-dihydroxyvitamin D(3) on prostatic epithelial cells. (1995) (20)
- Loss of α2‐macroglobulin and epidermal growth factor surface binding induced by phenothiazines and naphthalene sulfonamides (1984) (20)
- The effect of various thyroxine analogues on suppression of I 131 uptake by the rat thyroid. (1959) (19)
- Cloning and characterization of the gene encoding the ADP-ribosylation factor in Candida albicans. (1992) (19)
- 1 , 25-Dihydroxyvitamin D 3 Receptors and Hormonal Responses in Cloned Human Skeletal Muscle Cells * (2008) (19)
- Characteristics of 22-oxacalcitriol (OCT) and 2β-(3-hydroxypropoxy)-calcitriol (ED-71). (1997) (19)
- Modulation of vitamin d receptor activity by the corepressor hairless: differential effects of hairless isoforms. (2009) (19)
- Vitamin D and prostate cancer. (1995) (19)
- Ketoconazole binds to the intracellular corticosteroid-binding protein in Candida albicans. (1983) (18)
- Modulation of 1,25‐dihydroxyvitamin D3 receptor binding and action by sodium butyrate in cultured pig kidney cells (LLC‐PK1) (1987) (18)
- Nonsteroidal anti-inflammatory drugs cause sodium and water retention in the rat. (1978) (18)
- Conceptually new 20-epi-22-oxa sulfone analogues of the hormone 1alpha,25-dihydroxyvitamin D(3): synthesis and biological evaluation. (2000) (18)
- Report of two unrelated patients with hereditary vitamin D resistant rickets due to the same novel mutation in the vitamin D receptor (2011) (18)
- Unexpected presence of estrogens in culture medium supplements: subsequent metabolism by the yeast Sacchromyces cerevisiae. (1986) (18)
- Racial, geographic, genetic, and body habitus effects on vitamin D metabolism. (1997) (17)
- 1,25-Dihydroxyvitamin D3 receptors in mouse colon. (1981) (16)
- Potentiation of the growth-inhibitory effects of vitamin D in prostate cancer by genistein. (2007) (16)
- Enteral calcium infusion used successfully as treatment for a patient with hereditary vitamin D resistant rickets (HVDRR) without alopecia: a novel mutation. (2013) (16)
- Irestatin, a potent inhibitor of IRE1{alpha} and the unfolded protein response, is a hypoxia-selective cytotoxin and impairs tumor growth (2007) (15)
- Vitamin D metabolism: the effects of aging. (1997) (15)
- Relationship among 25-hydroxyvitamin D concentrations, insulin action, and cardiovascular disease risk in patients with essential hypertension. (2015) (15)
- Chemoprevention of colon cancer by vitamin D3 and its metabolites/analogs. (1997) (14)
- Enhanced Coactivator Binding and Transcriptional Activation of Mutant Vitamin D Receptors From Patients With Hereditary 1,25‐Dihydroxyvitamin D‐Resistant Rickets by Phosphorylation and Vitamin D Analogs (2005) (14)
- 1,25-Dihydroxyvitamin D 3 Induction of Nerve Growth Factor in L929 Mouse Fibroblasts: Effect of Vitamin D Receptor Regulation and Potency of Vitamin D 3 Analogs* (1996) (14)
- induced Growth Inhibition 325-Hydroxyvitamin D Cells Correlates with Decreased Susceptibility to-hydroxylase Activity in Human Prostate Cancer α Reduced 1 Updated (2001) (14)
- Vitamin D receptor gene variants and osteoporosis: a contributor to the polygenic control of bone density. (1997) (14)
- Inhibition of prostaglandin synthesis and actions contributes to the beneficial effects of calcitriol in prostate cancer (2009) (14)
- Vitamin D supplementation decreases serum 27-hydroxycholesterol in a pilot breast cancer trial (2018) (14)
- Cleavage of the rat intestinal 1,25-dihydroxyvitamin D3 receptor by an endogenous protease to a form with defective DNA binding. (1986) (14)
- Identification of tumor-autonomous and indirect effects of vitamin D action that inhibit breast cancer growth and tumor progression (2017) (14)
- Inhibition of aldosterone synthesis in rat adrenal cells by nicotine and related constituents of tobacco smoke. (1994) (13)
- CHAPTER 13 – Vitamin D: Biology, Action, and Clinical Implications (2008) (13)
- Vitamin D in pregnancy, the fetoplacental unit, and lactation. (1997) (13)
- 16β-Hydroxydehydroepiandrosterone: the Dichotomy Between Renal Receptor Binding and Urinary Electrolyte Activity1 (1976) (12)
- Vitamin D: Cancer and differentiation (2011) (12)
- Saccharomyces cerevisiae produces a yeast substance that exhibits estrogenic activity in mammalian systems. (1984) (12)
- Vitamin D action on tooth development and biomineralization. (1997) (12)
- Chapter 65 – Hereditary 1,25-Dihydroxyvitamin-D-Resistant Rickets (2011) (11)
- Glucocorticoids and regulation of phosphoenolpyruvate carboxykinase activity in rat brown adipose tissue. (1978) (11)
- 27‐Hydroxycholesterol, an Endogenous SERM, and Risk of Fracture in Postmenopausal Women: A Nested Case‐Cohort Study in the Women's Health Initiative (2018) (11)
- Glucocorticoid receptors and regulation of phosphoenolpyruvate carboxykinase activity in rat kidney and adipose tissue. (1977) (11)
- A low-calcemic vitamin D analog (Ro 25-4020) inhibits the growth of LNCaP human prostate cancer cells with increased potency by producing an active 24-oxo metabolite (Ro 29-9970). (2003) (10)
- Vitamin D and the parathyroid glands. (1997) (10)
- Structural and functional determinants of DNA binding and dimerization by the vitamin D receptor. (1997) (9)
- Chemistry and design: structural biology of vitamin D action (1997) (9)
- Human vitamin D receptor mutations: identification of molecular defects in hypocalcemic vitamin D resistant rickets. (1989) (9)
- Synthesis and biological evaluation of 1α,25-dihydroxyvitamin D(3) analogues hydroxymethylated at C-26. (2011) (8)
- VITAMIN D RECEPTOR MUTATIONS AND HEREDITARY 1,25-DIHYDROXYVITAMIN D RESISTANT RICKETS (1991) (8)
- A new enzyme-linked immunosorbant assay for the measurement of human vitamin D receptor. (2001) (8)
- Williams syndrome transcription factor (WSTF) acts as an activator of estrogen receptor signaling in breast cancer cells and the effect can be abrogated by 1α,25-dihydroxyvitamin D3 (2017) (8)
- Glucocorticoid receptors and inhibition of bone cell growth in primary culture. (1976) (8)
- Modulation of PTH-stimulated cyclic AMP in cultured rodent bone cells: The effects of 1,25(OH)2 vitamin D3 and its interaction with glucocorticoids (1984) (8)
- The binding of 18-hydroxydeoxycorticosterone and 18-hydroxycorticosterone to mineralocorticoid and glucocorticoid receptors in the rat kidney. (1973) (7)
- Pharmacology of vitamin D preparations. (1997) (7)
- Molecular Defects in the Vitamin D Receptor Associated with Hereditary 1,25-Dihydroxyvitamin D-Resistant Rickets (HVDRR) (2010) (7)
- Other vitamin D target tissues: vitamin D actions in cardiovascular tissue and muscle, endocrine and reproductive tissues, and liver and lung. (1997) (7)
- CHAPTER 48 – Perinatal Vitamin D Actions (1997) (7)
- Mineralocorticoid receptors and 18-hydroxydeoxycorticosterone binding in the kidney of the spontaneously hypertensive rat. (1974) (6)
- A rationale for treatment of hereditary vitamin D-resistant rickets with analogs of 1 alpha,25-dihydroxyvitamin D(3). (2001) (6)
- Binding of some non-steroidal anti-inflammatory drugs to glucocorticoid receptors in vitro. (1978) (6)
- Glucocorticoid and vitamin D interactions. (1997) (6)
- Association of 25‐hydroxyvitamin D levels and cutaneous melanoma: A nested case‐control study of the Women's Health Initiative Observation Study (2018) (6)
- Salt-induced activation of 1,25-dihydroxyvitamin D3 receptors to a DNA binding form. (1987) (5)
- Vitamin D compounds and analogs: effects on normal and abnormal Hematopoiesis. (1997) (4)
- Chemopreventive Properties of Tolfenamic Acid: A Mechanistic Review. (2018) (4)
- Biological activity of 19‐nor, 10‐keto, 25‐hydroxyvitamin D3 (1987) (4)
- 1,25-dihydroxyvitamin D3 interactions with local factors in bone remodeling. (1997) (4)
- Phase II study evaluating oral triamcinolone in patients with androgen-independent prostate cancer. (2006) (4)
- Heterogenetiy of glucocorticoid binders: a high affinity triamcinolone acetonide binder in bovine serum. (1980) (3)
- Overview of vitamin D actions in cancer (2018) (3)
- Anti-inflammatory Activity of Calcitriol in Cancer (2011) (3)
- Case Report: Hypercholesterolemia “Lean Mass Hyper-Responder” Phenotype Presents in the Context of a Low Saturated Fat Carbohydrate-Restricted Diet (2022) (3)
- Genetic Disorders Of Vitamin D Synthesis and Action (2018) (2)
- Identification of Irestatins: A Novel Class of Hypoxia Targeted Cancer Therapeutics (2007) (2)
- 1 a ,25-Dihydroxyvitamin D 3 Down-Regulates Estrogen Receptor Abundance and Suppresses Estrogen Actions in MCF-7 Human Breast Cancer Cells 1 (2000) (2)
- International Congress on Hormonal Steroids and Hormones and Cancer The role of vitamin D and retinoids in controlling prostate cancer progression (2003) (2)
- Anti-inflammatory Activity of Calcitriol That Contributes to Its Therapeutic and Chemopreventive Effects in Prostate Cancer (2010) (2)
- Chapter 33 – Genetic Disorders of Vitamin D Synthesis and Action (2013) (2)
- Vitamin D Deficiency, Rickets and Osteomalacia (2003) (2)
- Prediagnostic 25-Hydroxyvitamin D Concentrations in Relation to Tumor Molecular Alterations and Risk of Breast Cancer Recurrence (2020) (1)
- Identification of 17 fi-estradiol as the estrogenic substance in Saccharomyces cerevisiae ( yeast / steroid hormone / estrogen receptor ) (1999) (1)
- Hereditary Resistance to Vitamin D (1999) (1)
- 84. Heterogeneity of glucocorticoid binding sites: a classical and a unique binder in bovine tissues (1978) (1)
- 16Beta-hydroxydehydroepiandrosterone: the dichotomy between renal receptor binding and urinary electrolyte activity. (1976) (1)
- Thyroidal C cells and medullary thyroid carcinoma as target tissues for vitamin D action. (1997) (1)
- The mechanism of action of spirolactones. (1975) (1)
- 130 Association of 25-hydroxyvitamin D levels and cutaneous melanoma in postmenopausal women in the Women’s Health Initiative study (2016) (1)
- Comprar Vitamin D | David Feldman | 9780123819789 | Academic Press (2011) (0)
- Agonist and antimineralocortieoid activities of spirolactones (2003) (0)
- Vitamin D-Androgen Interaction in Prostate Cancer (1999) (0)
- Abstract 5635: Vitamin D supplementation decreases serum 27-hydroxycholesterol and expression of CYP27A1 in tumors of breast cancer patients (2017) (0)
- Interactions Between Vitamin D and Breast Cancer (2009) (0)
- DNA binding properties of the vitamin D3 receptor zinc finger region (1992) (0)
- Nutritional Genomics in Cancer Processes Pathways Mediating the Growth-Inhibitory Actions of Vitamin D in Prostate Cancer 1 (2003) (0)
- EnhancedAnticancerActivity and Increased HypercalcemicToxicity in aMouseXenograft Modelof ProstateCancer (2012) (0)
- Vitamin D and cancer (2015) (0)
- A review of: “The Effects of Hostile Environments on Coattings and Plastics, Acs. D. P. Garner and G. A. Stahl (Editors): Symposium Series 229, American Chemical Society, Washington, D.C., 1983, 339 pp., U.S. and Canada $47.95, export $57.95.” (1985) (0)
- The Molecular Basis of Hereditary 1 , 25Dihydroxyvitamin 25Dihydroxyvitamin 25Dihydroxyvitamin D 3 Resistant Rickets in Seven Related Families (2013) (0)
- O 0 1 , 25-Dihydroxyvitamin D 3 Receptors in Human Epithelial Cancer Cell Lines ' (2006) (0)
- Oncology: Prostate/Testis/Penis/Urethra PROSTATE SPECIFIC ANTIGEN LEVELS IN YOUNG ADULTHOOD PREDICT PROSTATE CANCER RISK: RESULTS FROM A COHORT OF BLACK AND WHITE AMERICANS (2005) (0)
- Elimination of Salmonellae from Animal Glandular Products (1969) (0)
- 062-S: Serum Steroid Hormones in Young Manhood and the Risk of Subsequent Prostate Cancer (2005) (0)
- Editorials (1894) (0)
- Hereditary 1 , 25-Dihydroxyvitamin (2004) (0)
- Vitamin D. Treatment of Prostate Cancer: The Inhibitory Role of IGFBP-3 (2005) (0)
- 228. Ontogeny of rat hepatic glucocorticoid receptors (1974) (0)
- PROSTATIC CONCENTRATION OF SOY ISOFLAVONE EXCEEDS SERUM AFTER DIETARY SUPPLEMENTATION (2009) (0)
- Abstract A85: Prediagnostic 25-hydroxyvitamin D concentrations in relation to tumor molecular alterations and risk of breast cancer recurrence (2020) (0)
- Vitamin D Receptor Start Codon Polymorphism ( FokI ) and Prostate Cancer Progression 1 (2003) (0)
- The Role of Vitamin D Stimulation of Mullerian Inhibiting Substance (MIS) in Prostate Cancer Therapy (2007) (0)
- Effect of dexmedetomidine, an imidazoline alpha-2 adrenergic agonist, on steroidogenesis: in vivo and in vitro studies (1990) (0)
- Book Review:Multiple Molecular Forms of Steroid Hormone Receptors. M. K. Agarwal (1978) (0)
- Treatment of Prostate Cancer : The Inhibitory Role of IGFBP-3 PRINCIPAL INVESTIGATOR : (2006) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With David Feldman?
David Feldman is affiliated with the following schools:
